Related references
Note: Only part of the references are listed.Structural and functional characterization explains loss of dNTPase activity of the cancer-specific R366C/H mutant SAMHD1 proteins
Nicole E. Bowen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2021)
Pharmacological Modulation of SAMHD1 Activity by CDK4/6 Inhibitors Improves Anticancer Therapy
Marc Castellvi et al.
CANCERS (2020)
Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes
Ferran Nadeu et al.
BLOOD (2020)
CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1- mantle cell lymphoma
David Martin-Garcia et al.
BLOOD (2019)
SAMHD1 is recurrently mutated in T-cell prolymphocytic leukemia
Patricia Johansson et al.
BLOOD CANCER JOURNAL (2018)
SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia (vol 23, pg 250, 2017)
Constanze Schneider et al.
NATURE MEDICINE (2017)
Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies
Nikolas Herold et al.
NATURE MEDICINE (2017)
SAMHD1 acetylation enhances its deoxynucleotide triphosphohydrolase activity and promotes cancer cell proliferation
Eun Ji Lee et al.
Oncotarget (2017)
SAMHD1 Promotes DNA End Resection to Facilitate DNA Repair by Homologous Recombination
Waaqo Daddacha et al.
CELL REPORTS (2017)
SAMHD1 is a barrier to antimetabolite-based cancer therapies
Sean G. Rudd et al.
MOLECULAR & CELLULAR ONCOLOGY (2017)
Chromatin Accessibility Landscape of Cutaneous T Cell Lymphoma and Dynamic Response to HDAC Inhibitors
Kun Qu et al.
CANCER CELL (2017)
Heterozygous colon cancer-associated mutations of SAMHD1 have functional significance
Matilda Rentoft et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
R-CHOP or R-HyperCVAD With or Without Autologous Stem Cell Transplantation for Older Patients With Mantle Cell Lymphoma
Zachary Frosch et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2015)
SAMHD1 is down regulated in lung cancer by methylation and inhibits tumor cell proliferation
Wang Jia-lei et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2014)
SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage
Ruth Clifford et al.
BLOOD (2014)
Downregulation of SAMHD1 Expression Correlates with Promoter DNA Methylation in Sezary Syndrome Patients
Suresh de Silva et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2014)
A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213
S. H. Bernstein et al.
ANNALS OF ONCOLOGY (2013)
CCND2 rearrangements are the most frequent genetic events in cyclin D1- mantle cell lymphoma
Itziar Salaverria et al.
BLOOD (2013)
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
Mathias J. Rummel et al.
LANCET (2013)
The deoxynucleotide triphosphohydrolase SAMHD1 is a major regulator of DNA precursor pools in mammalian cells
Elisa Franzolin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Phosphorylation of SAMHD1 by Cyclin A2/CDK1 Regulates Its Restriction Activity toward HIV-1
Alexandra Cribier et al.
CELL REPORTS (2013)
Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi
Francesco Merli et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
The Ability of Primate Lentiviruses to Degrade the Monocyte Restriction Factor SAMHD1 Preceded the Birth of the Viral Accessory Protein Vpx
Efrem S. Lim et al.
CELL HOST & MICROBE (2012)
VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study
Julie E. Chang et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma
Stephen E. Spurgeon et al.
LEUKEMIA & LYMPHOMA (2011)
HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase
David C. Goldstone et al.
NATURE (2011)
SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx
Nadine Laguette et al.
NATURE (2011)
Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma
R. Schaffel et al.
ANNALS OF ONCOLOGY (2010)
The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)
Christian H. Geisler et al.
BLOOD (2010)
Immunochemotherapy and Autologous Stem-Cell Transplantation for Untreated Patients With Mantle-Cell Lymphoma: CALGB 59909
Lloyd E. Damon et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Mutations involved in Aicardi-Goutieres syndrome implicate SAMHD1 as regulator of the innate immune response
Gillian I. Rice et al.
NATURE GENETICS (2009)
Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies
P. Martin et al.
ANNALS OF ONCOLOGY (2008)
Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group
David J. Inwards et al.
CANCER (2008)
The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma
T Katzenberger et al.
BLOOD (2006)
Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma:: Results of a prospective randomized trial of the German low grade lymphoma study group (GLSG)
G Lenz et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Transplantation in patients with diffuse mantle cell lymphoma in first disease remission the prognostic value of β2-microglobulin and the tumor score
IF Khouri et al.
CANCER (2003)
Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma
J Mangel et al.
SEMINARS IN ONCOLOGY (2002)
Share Paper
